We develop transformative medicines for severe diseases using our Confo® GPCR technology.
In addition to advancing our own portfolio, we are engaging in strategic partnerships with other biopharmaceutical organizations in non-competing disease areas. We have secured revenue-generating drug discovery partnerships with leading pharma companies, as well as drug discovery collaborations in support of our proprietary programs.


In 2017, we initiated discovery collaborations with Roche and Lundbeck in the field of neuroscience.

F. Hoffmann-La Roche Ltd

Confo Therapeutics, an emerging drug discovery company, announced today that it has entered into a research collaboration and license agreement with Roche for the discovery …

Lundbeck A/S

Confo Therapeutics, an emerging drug discovery company, today announced that it has entered into a drug discovery collaboration with H. Lundbeck A/S, a global pharmaceutical company …


As we develop our science and our pipeline, we seek to further develop our portfolio of strategic collaborations with key partners. Get in touch to discuss partnering opportunities.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.